News

The US and the world must appreciate the role of the pharmaceutical industry—the investigators, physicians and business leaders—who are rescuing the world from COVID-19. It’s the medical breakthrough of our lifetime.

In part 1 of this article series, Dr. Concoff dusts off the crystal ball to envision the future of the practice of rheumatology, in particular the role of telemedicine during the COVID-19 pandemic and beyond.

Some studies have suggested an increase in the incidence of neuropsychiatric disorders in rheumatic patients may be due to the immunological mechanisms of the disease itself.

 Study Highlights Osteoporosis Risk in Gay Men

Non-heterosexual minority men have a greater risk of poor bone health than heterosexual men, and this risk appears to be independent of lifestyle and psychosocial factors, suggests a study published in the American Journal of Human Biology.

Combo Medications May Reduce Need for Prednisone in Lung Disease Treatment

Adding rituximab to mycophenolate mofetil may necessitate a lower average daily dose of prednisone in patients with recalcitrant connective tissue disease–associated interstitial lung disease, but the combination treatment may not improve pulmonary function, shows a new study.

Stress Can Take Its Toll Rheumatic Disease

Anxiety and depression are not uncommon among lupus patients, show studies recently presented at the annual meeting of the American College of Rheumatology.